Successful study of Infectious Bronchitis in chickens
The Quigley Corp. has announced positive results from a study* conducted in chickens to evaluate the anti-viral activity of its compound QR448(a).
The compound was administered to chicks that had been infected with Infectious Bronchitis Virus (IBV). Data indicates that QR448(a) is efficacious against an IBV challenge in 2-week-old specific pathogen-free (SPF) chicks, confirming previous results indicating that treatment with QR448(a) before or after viral exposure has the potential to lessen or prevent disease.
Preventing and treating infectious bronchitis caused by IBV is a worldwide concern of the poultry industry. This disease may result in lowered weight gains, poor production, low egg quality, and in sever cases, mortality
The Company began the study after receiving feedback from poultry industry leaders who expressed an increasing need for additional products to combat IBV.
The Company began the study after receiving feedback from poultry industry leaders who expressed an increasing need for additional products to combat IBV.
Richard Rosenbloom, executive vice president and COO of Quigley Pharma : “We believe this innovative, non-vaccine, broad spectrum antiviral has the potential to offer the poultry industry a natural base solution to this growing problem.”
* This study was carried out by the Quigley Corp’s wholly owned subsidiary, Quigley Pharma Inc, and conducted by Dr Mark Jackwood Professor, Department of Population Health, College of Veterinary Medicine, University of Georgia.
Related link:
Join 31,000+ subscribers
Subscribe to our newsletter to stay updated about all the need-to-know content in the poultry sector, three times a week.
